FindTrial
Sign In

Clinical and neurobiological characterisation of "muscarinic receptor-deficit schizophrenia (MRDS)"

Clinical and neurobiological characterisation of "muscarinic receptor-deficit schizophrenia (MRDS)" - neuroimaging of MRDS

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38703
Enrollment
90
Registered
2013-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRDS psychosis

Interventions

On two occasions non- invasive 3.0 Tesla fMRI, DTI, and MRS recording will be conducted following a single dose of 4 mg biperiden or placebo, administered orally. For the SPECT study a registered, w

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Patients with first-episode psychosis as defined by the standardised criteria of the CASH -Antipsychotic naïve -Duration of untreated psychosis no more than 1 year. -16 years and older

Exclusion criteria

Exclusion criteria: -Use of antipsychotics or anticholinergics -Contraindications for MRI -Severe neurological, endocrine or psychiatric disorders -Pregnancy -Current use of recreational drugs; participants must be abstinent of recreational drugs such as cannabis at least 4 weaks prior to participation. -Tardive dyskinesia

Design outcomes

Primary

MeasureTime frame
-M1 receptor binding: ROI*s will be the hippocampus, striatum and dorsolateral prefrontal cortex. -BOLD signal activation during cognitive tasks PAL (40) and ER -40 (62) under cholinergic challenge and in placebo. (ROI*s DLPFC, hippocampus, and striatum). -Neuropsychological tests: CANTAB battery for schizophrenia.—

Secondary

MeasureTime frame
-DTI -RSfMRI -MRS placebo & biperideen -(Epi)genetics—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)